Compounds > quinidine
Page last updated: 2024-08-17

quinidine and Congenital Myasthenia

quinidine has been researched along with Congenital Myasthenia in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beeson, D; Lee, M; Palace, J1
Eymard, B1
Endreffy, E; Gajda, A; Gergev, G; Karcagi, V; Szabó, H; Szabó, N; Sztriha, L; Túri, S1
Brehm, P; Mandel, G; Mongeon, R; Walogorsky, M; Wen, H1
Engel, AG; Fukodome, T; Harper, CM1
Fukunaga, H; Sonoda, Y1
Crielaard, JM; Hansen, I; Wang, FC; Zeevaert, B1

Reviews

3 review(s) available for quinidine and Congenital Myasthenia

ArticleYear
Therapeutic strategies for congenital myasthenic syndromes.
    Annals of the New York Academy of Sciences, 2018, Volume: 1412, Issue:1

    Topics: Adrenergic beta-Agonists; Breast Feeding; Cholinergic Antagonists; Cholinesterase Inhibitors; Female; Fluoxetine; Humans; Infant; Infant, Newborn; Mutation; Myasthenic Syndromes, Congenital; Neuromuscular Junction; Pregnancy; Pregnancy Complications; Quinidine; Receptors, Cholinergic

2018
[Congenital myasthenic syndromes: repurposing does not simplify access de facto - Clinical use of innovative, repurposed or off-label therapies: a real life experience (4)].
    Medecine sciences : M/S, 2019, Volume: 35 Hors série n° 1

    Topics: Albuterol; Cholinesterase Inhibitors; Drug Repositioning; Ephedrine; Health Services Accessibility; Humans; Myasthenic Syndromes, Congenital; Off-Label Use; Practice Patterns, Physicians'; Quality of Life; Quinidine; Therapies, Investigational; Treatment Outcome

2019
[Congenital myasthenic syndrome (CMS) caused by postsynaptic defects].
    Ryoikibetsu shokogun shirizu, 2001, Issue:36

    Topics: Acetylcholine; Anti-Arrhythmia Agents; Diagnosis, Differential; Humans; Mutation; Myasthenic Syndromes, Congenital; Quinidine; Receptors, Cholinergic

2001

Other Studies

4 other study(ies) available for quinidine and Congenital Myasthenia

ArticleYear
Congenital myasthenic syndromes and transient myasthenia gravis.
    Ideggyogyaszati szemle, 2013, May-30, Volume: 66, Issue:5-6

    Topics: Child; Cholinesterase Inhibitors; Diagnosis, Differential; Female; Gene Deletion; Genetic Testing; Humans; Immunoglobulin G; Infant; Intelligence Tests; Myasthenia Gravis, Neonatal; Myasthenic Syndromes, Congenital; Neuropsychological Tests; Quinidine; Treatment Outcome

2013
Acetylcholine receptor gating in a zebrafish model for slow-channel syndrome.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Jun-06, Volume: 32, Issue:23

    Topics: Action Potentials; Animals; Calcium; Channelopathies; Cholinergic Agonists; Cholinergic Antagonists; Dose-Response Relationship, Drug; Ion Channel Gating; Isomerism; Movement; Muscle, Skeletal; Myasthenic Syndromes, Congenital; Oocytes; Patch-Clamp Techniques; Quinidine; Receptors, Cholinergic; Synaptic Transmission; Xenopus; Zebrafish

2012
Treatment of slow-channel congenital myasthenic syndrome with fluoxetine.
    Neurology, 2003, May-27, Volume: 60, Issue:10

    Topics: Adult; Cholinergic Antagonists; Drug Evaluation; Drug Hypersensitivity; Female; Fluoxetine; Genes, Dominant; Humans; Mutation, Missense; Myasthenic Syndromes, Congenital; Point Mutation; Quinidine; Receptors, Cholinergic; Treatment Outcome

2003
[Slow channel syndrome due to an autosomal translocation at 2q31-9p27].
    Revue neurologique, 2002, Volume: 158, Issue:5 Pt 1

    Topics: Action Potentials; Adult; Autoimmune Diseases; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 9; Diagnosis, Differential; Electromyography; Genetic Heterogeneity; Humans; In Situ Hybridization, Fluorescence; Ion Transport; Male; Muscarinic Antagonists; Myasthenia Gravis; Myasthenic Syndromes, Congenital; Neostigmine; Neural Conduction; Protein Subunits; Quinidine; Receptors, Muscarinic; Translocation, Genetic

2002